Noscendo receives new funding

The start-up wants to identify pathogens with software. The concept once again convinces investors.

Start-up Noscendo secures new capital in its Series B funding round to improve its diagnosis of infectious diseases. In the process, Revent and an undisclosed family office with a focus on life sciences invest. Existing investors Earlybird Health, Wieland Capital, Paua Ventures and High-Tech Gründerfonds (HTGF) also reportedly participated again. The exact amount of the investments is not known.

With the new funding, Noscendo intends to expand its operating business, invest in the further market launch of its Disqver tests based on IVD (in vitro diagnostics) software, expand its management team and accelerate the development of its product platform. As a result, additional products are expected to be launched this year.

"With Disqver, patients can be treated faster, in a more targeted manner and based on reliable information about the responsible pathogens. This is helpful for both physicians and patients," says Philip Stevens, co-founder and CEO of Noscendo. He co-founded the company with Silke Grumaz and Peter Haug in 2018. The startup claims to be able to detect more than 1,500 different pathogens from patient samples within 24 hours using a single test. This, he says, is possible thanks to the company's proprietary platform.